drugset
drugset / Trial / NCT02782403

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

NCT02782403 ↗

Phase 1 Terminated 4 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of axitinib and bosutinib and how well they work in treating patients with chronic, accelerated, or blastic phase chronic myeloid leukemia. Axitinib and bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2017-03-20
Primary completion
2019-11-11
Completion
2019-11-11

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to other competing studies.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule — Oral
Subject Bosutinib Small molecule — Oral

Indications

Philadelphia-positive myelogenous leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive leukemia, myeloid, accelerated-phase